WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2022-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dystonia in Wilson's disease represent a major issue. The persistence of disabling motor symptoms despite medical treatments justifies conducting a study on deep brain stimulation (DBS) in Wilson's disease (WD). For bradykinetic patients, subthalamic nucleus (STN) could be considered as a better target than the globus pallidus (GPi). For patients with hyperkinetic dystonia, the internal globus pallidus (GPi) will be chosen as the target of DBS.

The investigators hypothesize that STN DBS will improve Wilson's disease patients, who, despite copper chelators drugs, are still impaired by severe dystonia and akinesia (more or less associated with other movement disorders).

The investigators primary objective is to demonstrate the efficacy of STN/GPi DBS on dystonia associated with Wilson's disease.

Secondary objectives:

* To evaluate the impact of STN/GPi DBS on other movements disorders (tremor, Parkinsonism, chorea) observed in Wilson's disease.
* To describe cognitive status of patients and to evaluate the consequences of STN/GPi DBS on cognition and behavioral aspects of the disease.
* To evaluate the consequences of the stimulation on speech and swallowing.
* To evaluate the social impact of STN/GPi DBS in Wilson's disease.
* To evaluate the safety of STN/GPi DBS in the specific context of Wilson's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deep Brain Stimulation in Patients With Dystonia

NCT00773604

Dystonia

COMPLETED NA

Deep Brain Stimulation Surgery for Movement Disorders

NCT01581580

Parkinson's Disease Essential Tremor Dystonia

RECRUITING NA

Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM

NCT02823158

Central Nervous System Disease Basal Ganglia Disease Movement Disorders +2 more

TERMINATED NA

Chronic Effects of DBS in Parkinson's Disease and Dystonia

NCT01934296

Parkinson's Disease Isolated Dystonia

COMPLETED NA

Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia

NCT00142259

Dystonia

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

4 periods of stimulation on and off, sequence randomized at Day 0.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Dystonia Wilson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stimulation "on"

The deep brain stimulation is "on"

Group Type EXPERIMENTAL

Medtronic, Activa® PC "on"

Intervention Type DEVICE

Stimulation "off"

The deep brain stimulation is "off"

Group Type SHAM_COMPARATOR

Medtronic, Activa® PC "off"

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medtronic, Activa® PC "on"

Intervention Type DEVICE

Medtronic, Activa® PC "off"

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 and \< 60 years.
* Severe neurological form of Wilson's disease with predominant dystonia and akinetic-rigid syndrome, despite optimized treatment stabilized for at least 6 months.
* Important disability due to abnormal movements (Rankin score=2 to 4).
* Absence of dementia (MMS \> 24 and BREF \> 15).
* Stable psychiatric status and absence of severe depression (BDI \<28).
* Social security coverage.
* Signature of informed consent. (signature of legal guardian for subjects under protection)

Exclusion Criteria

* Severe hepatopathy with coagulation disorders (Platelet count \< 100 G / l; INR \> 1.5; V factor deficit; low level of fibrinogen \< 1g/dL; increased of fibrin degradation products; low level of antithrombin).
* Liver transplanted patients \< 2 years
* Patients under immunosupressive drugs and corticoids regimen.
* Participation to another biomedical research involving any drugs.
* Severe and uncontrolled psychosis or depression.
* Major atrophy on brain MRI that could represent a problem for leads implantation.
* Necrosis of the STN/GPi on brain MRI.
* Female subjects who are pregnant or lactating.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No